FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899367069> ?p ?o ?g. }

• W2899367069 endingPage "50" @default.
• W2899367069 startingPage "44" @default.
• W2899367069 abstract "Erythropoietin (EPO) is being trialled in preterm infants to reduce brain injury, but high doses increase lung injury in ventilated preterm lambs. We aimed to determine whether early administration of lower doses of EPO could reduce ventilation-induced lung injury and systemic inflammation in preterm lambs. Ventilation was initiated in anaesthetized preterm lambs [125 ± 1 (SD) days gestation] using an injurious strategy for the first 15 min. Lambs were subsequently ventilated with a protective strategy for a total of 2 h. Lambs were randomized to receive either intravenous saline (Vent; n = 7) or intravenous 300 ( n = 5), 1,000 (EPO 1000 ; n = 5), or 3,000 (EPO 3000 ; n = 5) IU/kg of human recombinant EPO via an umbilical vein. Lung tissue was collected for molecular and histological assessment of inflammation and injury and compared with unventilated control lambs (UVC; n = 8). All ventilated groups had similar blood gas and ventilation parameters, but EPO 1000 lambs had a lower fraction of inspired oxygen requirement and lower alveolar–arterial difference in oxygen. Vent and EPO lambs had increased lung interleukin (IL)-1β, IL-6, and IL-8 mRNA, early lung injury genes connective tissue growth factor, early growth response protein 1, and cysteine-rich 61, and liver serum amyloid A3 mRNA compared with UVCs; no difference was observed between Vent and EPO groups. Histological lung injury was increased in Vent and EPO groups compared with UVCs, but EPO 3000 lambs had increased lung injury scores compared with VENT only. Early low-doses of EPO do not exacerbate ventilation-induced lung inflammation and injury and do not provide any short-term respiratory benefit. High doses (≥3,000 IU/kg) likely exacerbate lung inflammation and injury in ventilated preterm lambs. NEW & NOTEWORTHY Trials are ongoing to assess the efficacy of erythropoietin (EPO) to provide neuroprotection for preterm infants. However, high doses of EPO increase ventilation-induced lung injury (VILI) in preterm lambs. We investigated whether early lower doses of EPO may reduce VILI. We found that lower doses did not reduce, but did not increase, VILI, while high doses (≥3,000 IU/kg) increase VILI. Therefore, lower doses of EPO should be used in preterm infants, particularly those receiving respiratory support." @default.
• W2899367069 created "2018-11-09" @default.
• W2899367069 creator A5017688800 @default.
• W2899367069 creator A5019419254 @default.
• W2899367069 creator A5023962612 @default.
• W2899367069 creator A5027553318 @default.
• W2899367069 creator A5046851239 @default.
• W2899367069 creator A5048084181 @default.
• W2899367069 creator A5059683473 @default.
• W2899367069 creator A5072495722 @default.
• W2899367069 creator A5078560982 @default.
• W2899367069 creator A5083028196 @default.
• W2899367069 creator A5090664161 @default.
• W2899367069 date "2019-01-01" @default.
• W2899367069 modified "2023-10-14" @default.
• W2899367069 title "Dose-dependent exacerbation of ventilation-induced lung injury by erythropoietin in preterm newborn lambs" @default.
• W2899367069 cites W1511141108 @default.
• W2899367069 cites W1906759767 @default.
• W2899367069 cites W1955340937 @default.
• W2899367069 cites W1964219654 @default.
• W2899367069 cites W1965214134 @default.
• W2899367069 cites W1969951251 @default.
• W2899367069 cites W1987299773 @default.
• W2899367069 cites W1988427585 @default.
• W2899367069 cites W2000041859 @default.
• W2899367069 cites W2017777919 @default.
• W2899367069 cites W2020591797 @default.
• W2899367069 cites W2049216735 @default.
• W2899367069 cites W2056777387 @default.
• W2899367069 cites W2063354453 @default.
• W2899367069 cites W2068064201 @default.
• W2899367069 cites W2085127147 @default.
• W2899367069 cites W2086715533 @default.
• W2899367069 cites W2132040570 @default.
• W2899367069 cites W2137183471 @default.
• W2899367069 cites W2139878559 @default.
• W2899367069 cites W2146384109 @default.
• W2899367069 cites W2153750008 @default.
• W2899367069 cites W2163634814 @default.
• W2899367069 cites W2342987015 @default.
• W2899367069 cites W2600076358 @default.
• W2899367069 cites W2789791369 @default.
• W2899367069 cites W4210288536 @default.
• W2899367069 doi "https://doi.org/10.1152/japplphysiol.00800.2018" @default.
• W2899367069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30382807" @default.
• W2899367069 hasPublicationYear "2019" @default.
• W2899367069 type Work @default.
• W2899367069 sameAs 2899367069 @default.
• W2899367069 citedByCount "9" @default.
• W2899367069 countsByYear W28993670692019 @default.
• W2899367069 countsByYear W28993670692020 @default.
• W2899367069 countsByYear W28993670692021 @default.
• W2899367069 countsByYear W28993670692022 @default.
• W2899367069 crossrefType "journal-article" @default.
• W2899367069 hasAuthorship W2899367069A5017688800 @default.
• W2899367069 hasAuthorship W2899367069A5019419254 @default.
• W2899367069 hasAuthorship W2899367069A5023962612 @default.
• W2899367069 hasAuthorship W2899367069A5027553318 @default.
• W2899367069 hasAuthorship W2899367069A5046851239 @default.
• W2899367069 hasAuthorship W2899367069A5048084181 @default.
• W2899367069 hasAuthorship W2899367069A5059683473 @default.
• W2899367069 hasAuthorship W2899367069A5072495722 @default.
• W2899367069 hasAuthorship W2899367069A5078560982 @default.
• W2899367069 hasAuthorship W2899367069A5083028196 @default.
• W2899367069 hasAuthorship W2899367069A5090664161 @default.
• W2899367069 hasBestOaLocation W28993670691 @default.
• W2899367069 hasConcept C126322002 @default.
• W2899367069 hasConcept C127413603 @default.
• W2899367069 hasConcept C134018914 @default.
• W2899367069 hasConcept C200457457 @default.
• W2899367069 hasConcept C2777080012 @default.
• W2899367069 hasConcept C2777714996 @default.
• W2899367069 hasConcept C2778534260 @default.
• W2899367069 hasConcept C2779234561 @default.
• W2899367069 hasConcept C42219234 @default.
• W2899367069 hasConcept C46973012 @default.
• W2899367069 hasConcept C54355233 @default.
• W2899367069 hasConcept C71924100 @default.
• W2899367069 hasConcept C78519656 @default.
• W2899367069 hasConcept C86803240 @default.
• W2899367069 hasConceptScore W2899367069C126322002 @default.
• W2899367069 hasConceptScore W2899367069C127413603 @default.
• W2899367069 hasConceptScore W2899367069C134018914 @default.
• W2899367069 hasConceptScore W2899367069C200457457 @default.
• W2899367069 hasConceptScore W2899367069C2777080012 @default.
• W2899367069 hasConceptScore W2899367069C2777714996 @default.
• W2899367069 hasConceptScore W2899367069C2778534260 @default.
• W2899367069 hasConceptScore W2899367069C2779234561 @default.
• W2899367069 hasConceptScore W2899367069C42219234 @default.
• W2899367069 hasConceptScore W2899367069C46973012 @default.
• W2899367069 hasConceptScore W2899367069C54355233 @default.
• W2899367069 hasConceptScore W2899367069C71924100 @default.
• W2899367069 hasConceptScore W2899367069C78519656 @default.
• W2899367069 hasConceptScore W2899367069C86803240 @default.
• W2899367069 hasFunder F4320320471 @default.
• W2899367069 hasFunder F4320334705 @default.
• W2899367069 hasIssue "1" @default.
• W2899367069 hasLocation W28993670691 @default.

• next